Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
20.04
USD
|
-0.30%
|
|
-11.01%
|
-44.85%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
631.6
|
479.5
|
2,302
|
3,111
|
1,950
|
1,078
|
-
|
-
|
Enterprise Value (EV)
1 |
631.6
|
479.5
|
2,302
|
3,111
|
1,331
|
1,078
|
1,078
|
1,078
|
P/E ratio
|
-8.12
x
|
-4.32
x
|
35.8
x
|
-24.4
x
|
-13.2
x
|
-4.26
x
|
-4.72
x
|
-7.38
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
776
x
|
562
x
|
11.5
x
|
57.7
x
|
21.3
x
|
71.4
x
|
12.2
x
|
5.1
x
|
EV / Revenue
|
776
x
|
562
x
|
11.5
x
|
57.7
x
|
21.3
x
|
71.4
x
|
12.2
x
|
5.1
x
|
EV / EBITDA
|
-
|
-4,310,881
x
|
31,491,761
x
|
-
|
-10,258,370
x
|
-
|
-
|
-
|
EV / FCF
|
-11.7
x
|
-5.95
x
|
25
x
|
-
|
-14.3
x
|
-4.45
x
|
-10.6
x
|
-9.12
x
|
FCF Yield
|
-8.56%
|
-16.8%
|
4%
|
-
|
-7.01%
|
-22.5%
|
-9.44%
|
-11%
|
Price to Book
|
-
|
-
|
-
|
-
|
3.44
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
39,897
|
39,921
|
46,594
|
51,627
|
53,665
|
53,772
|
-
|
-
|
Reference price
2 |
15.83
|
12.01
|
49.40
|
60.25
|
36.34
|
20.04
|
20.04
|
20.04
|
Announcement Date
|
2/12/20
|
2/11/21
|
2/17/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.814
|
0.853
|
200.6
|
53.9
|
91.37
|
15.09
|
88.26
|
211.1
|
EBITDA
|
-
|
-111.2
|
73.09
|
-
|
-190.1
|
-
|
-
|
-
|
EBIT
1 |
-85.7
|
-112.7
|
71.98
|
-131.6
|
-191
|
-289.5
|
-250
|
-160
|
Operating Margin
|
-10,527.89%
|
-13,216.18%
|
35.88%
|
-244.05%
|
-209.08%
|
-1,917.94%
|
-283.24%
|
-75.77%
|
Earnings before Tax (EBT)
1 |
-77.3
|
-111.4
|
71.92
|
-125.6
|
-160.5
|
-262.3
|
-263.5
|
-146.7
|
Net income
1 |
-77.68
|
-111.1
|
66.98
|
-116.9
|
-147
|
-250.5
|
-217.7
|
-164.6
|
Net margin
|
-9,542.63%
|
-13,029.78%
|
33.39%
|
-216.95%
|
-160.91%
|
-1,659.6%
|
-246.63%
|
-77.96%
|
EPS
2 |
-1.950
|
-2.780
|
1.380
|
-2.470
|
-2.760
|
-4.701
|
-4.242
|
-2.717
|
Free Cash Flow
1 |
-54.06
|
-80.56
|
92.03
|
-
|
-136.7
|
-242
|
-101.8
|
-118.1
|
FCF margin
|
-6,641.65%
|
-9,444.08%
|
45.88%
|
-
|
-149.63%
|
-1,603.62%
|
-115.29%
|
-55.93%
|
FCF Conversion (EBITDA)
|
-
|
-
|
125.91%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
137.41%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/12/20
|
2/11/21
|
2/17/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.172
|
1.153
|
1.312
|
1.517
|
49.92
|
2.169
|
4.019
|
84.87
|
0.316
|
0.05
|
1.839
|
1.839
|
11.36
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-33.09
|
-37.94
|
-43.21
|
-50.33
|
-0.072
|
-56.32
|
-66.5
|
10.31
|
-78.52
|
-81.53
|
-74.08
|
-73.69
|
-60.2
|
-80.73
|
-82.78
|
Operating Margin
|
-2,823.55%
|
-3,290.89%
|
-3,293.37%
|
-3,317.86%
|
-0.14%
|
-2,596.82%
|
-1,654.74%
|
12.15%
|
-24,846.52%
|
-163,056%
|
-4,028.63%
|
-4,007.7%
|
-529.88%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-33.1
|
-37.96
|
-42.57
|
-48.42
|
3.345
|
-49.78
|
-58.9
|
18.82
|
-70.62
|
-74.44
|
-68.65
|
-68.81
|
-51.58
|
-70.15
|
-72.18
|
Net income
1 |
-33.18
|
-36.29
|
-41.24
|
-45.76
|
6.349
|
-46.86
|
-54.6
|
21.91
|
-67.48
|
-72.24
|
-65.69
|
-65.94
|
-51.73
|
-75.58
|
-77.59
|
Net margin
|
-2,830.97%
|
-3,147.44%
|
-3,143.6%
|
-3,016.74%
|
12.72%
|
-2,160.63%
|
-1,358.42%
|
25.81%
|
-21,353.16%
|
-144,478%
|
-3,572.34%
|
-3,586.26%
|
-455.31%
|
-
|
-
|
EPS
2 |
-0.7100
|
-0.7800
|
-0.8800
|
-0.9700
|
0.1200
|
-0.8900
|
-1.030
|
0.3800
|
-1.260
|
-1.340
|
-1.222
|
-1.211
|
-1.013
|
-1.470
|
-1.515
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/17/22
|
5/5/22
|
8/8/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/15/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
619
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-54.1
|
-80.6
|
92
|
-
|
-137
|
-242
|
-102
|
-118
|
ROE (net income / shareholders' equity)
|
-26.1%
|
-48.6%
|
20.6%
|
-21.5%
|
-24.8%
|
-56.6%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-20.2%
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
727.2
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
10.50
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-1.330
|
-2.010
|
1.910
|
-
|
-2.520
|
-3.610
|
-5.130
|
-
|
Capex
1 |
0.56
|
0.2
|
0.58
|
-
|
2.81
|
0.28
|
0.53
|
0.59
|
Capex / Sales
|
68.18%
|
22.98%
|
0.29%
|
-
|
3.08%
|
1.82%
|
0.61%
|
0.28%
|
Announcement Date
|
2/12/20
|
2/11/21
|
2/17/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
20.04
USD Average target price
64.75
USD Spread / Average Target +223.10% Consensus |
1st Jan change
|
Capi.
|
---|
| -44.85% | 1.08B | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -1.69% | 21.78B | | -10.60% | 18.09B | | -41.25% | 16.72B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|